ABIRATERONE 250 EURODRUG is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in
adult men in combination with androgen deprivation therapy (ADT) (see PHARMACOLOGY: Pharmacodynamics under Actions); the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are
asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy
is not yet clinically indicated (see PHARMACOLOGY: Pharmacodynamics under Actions); the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based
chemotherapy regimen.